CytomX Therapeutics (6C1) Stock Statistics & Valuation Metrics
Total Valuation
CytomX Therapeutics has a market cap or net worth of EUR 455.02M. The enterprise value is EUR 495.53M.
- Market Cap
- EUR 455.02M
- Enterprise Value
- EUR 495.53M
Share Statistics
CytomX Therapeutics has 217,899,280 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 217,899,280
- Owned by Insiders
- 0.96%
- Owned by Institutions
- 35.01%
Financial Efficiency
CytomX Therapeutics’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -20.48%.
- Return on Equity (ROE)
- -0.18
- Return on Assets (ROA)
- -0.11
- Return on Invested Capital (ROIC)
- -20.48%
- Return on Capital Employed (ROCE)
- -0.21
- Revenue Per Employee
- 1.10M
- Profits Per Employee
- -251.71K
- Employee Count
- 69
- Asset Turnover
- 0.50
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of CytomX Therapeutics is -5.20. CytomX Therapeutics’s PEG ratio is 0.04.
- PE Ratio
- -5.20
- PS Ratio
- 27.86
- PB Ratio
- 1.70
- Price to FCF
- -6.18
- Price to Operating Cash Flow
- -6.22
- PEG Ratio
- 0.04
Income Statement
In the last 12 months, CytomX Therapeutics had revenue of 76.20M and earned -17.37M in profits. Earnings per share was -0.15.
- Revenue
- 76.20M
- Gross Profit
- 76.20M
- Operating Income
- -22.36M
- Pretax Income
- -17.13M
- Net Income
- -17.37M
- EBITDA
- -15.75M
- Earnings Per Share (EPS)
- -0.15
Cash Flow
In the last 12 months, operating cash flow was -82.41M and capital expenditures -74,000, giving a free cash flow of -82.48M billion.
- Operating Cash Flow
- -82.41M
- Free Cash Flow
- -82.48M
- Free Cash Flow per Share
- -0.38
Dividends & Yields
CytomX Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -16.18%
- Earnings Yield
- -15.55%
Stock Price Statistics
- Beta
- 1.44
- 52-Week Price Change
- -27.62%
- 50-Day Moving Average
- 2.49
- 200-Day Moving Average
- 3.31
- Relative Strength Index (RSI)
- 40.42
- Average Volume (3m)
- 616
Important Dates
CytomX Therapeutics upcoming earnings date is Nov 05, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
CytomX Therapeutics as a current ratio of 3.09, with Debt / Equity ratio of 4.28%
- Current Ratio
- 3.09
- Quick Ratio
- 3.09
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.53
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, CytomX Therapeutics has paid 238.00K in taxes.
- Income Tax
- 238.00K
- Effective Tax Rate
- -0.01
Enterprise Valuation
CytomX Therapeutics EV to EBITDA ratio is -6.35, with an EV/FCF ratio of -6.04.
- EV to Sales
- 27.23
- EV to EBITDA
- -6.35
- EV to Free Cash Flow
- -6.04
- EV to Operating Cash Flow
- -6.05
Balance Sheet
CytomX Therapeutics has EUR 330.28M in cash and marketable securities with EUR 5.70M in debt, giving a net cash position of EUR 324.58M billion.
- Cash & Marketable Securities
- EUR 330.28M
- Total Debt
- EUR 5.70M
- Net Cash
- EUR 324.58M
- Net Cash Per Share
- EUR 1.49
- Tangible Book Value Per Share
- EUR 1.37
Margins
Gross margin is 98.63%, with operating margin of -476.19%, and net profit margin of -435.21%.
- Gross Margin
- 98.63%
- Operating Margin
- -476.19%
- Pretax Margin
- -433.95%
- Net Profit Margin
- -435.21%
- EBITDA Margin
- -428.81%
- EBIT Margin
- -433.95%
Analyst Forecast
The average price target for CytomX Therapeutics is EUR 11.61, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 11.61
- Price Target Upside
- 479.77% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- -88.04%
- EPS Growth Forecast
- -172.87%
Scores
- Smart Score
- 3
- AI Score
- ―